Beyond THC and CBD
Cannabinoids are chemical compounds produced by the cannabis plant, that the human body can connect with. there are over 150 cannabinoids, THC and CBD being the most known ones.
THC – Tetrahydrocannabinol – is a very powerful pain reliever and CBD – Cannabidiol – has been shown to reduce seizures, chronic pain, anxiety, inflammation and assisted in many other medical matters.
Although Cannabis is well known by the effect of THC and CBD, there are many other cannabinoids and particular chemical compounds that are worth mentioning while considering pharmaceutical solutions, THCV (Tetrahydrocannabivarin), CBC (Cannabichromene) and CBG (Cannabigerol), to name a few.
THCV is an appetite suppressant, promotes the growth of new bone cells and also improves tremors, motor control, and brain lesions associated with Alzheimer’s disease.
CBC has anti-inflammatory properties and was shown to normalize gastrointestinal hypermotility.
CBG reduces acetylcholine-induced contractions in the human bladder, it can affects the central nervous system, decrease anxiety and muscle tension.
Many other Cannabinoids are currently being researched.
Moreover, the cannabis plant, as many other plants, produces terpenes – aromatic molecules, that are the main ingredient in essential oils. Terpenes can interact with the body and brain. Cannabinoids and terpenes influence the human body differently, and while interacting, the optimal therapeutic effect is achieved
The Cannabis industry
According to the United Nations, close to 160 million people around the world use Cannabis and the numbers are increasing abidingly.
This plant is known to contain more than 150 cannabinoids as well as dozens of terpenes, providing the Cannbis plant with its therapeutic effects.
While the current estimates of the legal Cannabis global market in 2017 were of arround $9.3 billion, the spending on legal cannabis worldwide is expected to reach more than $61 billion by 2028.
According to the Medical Marijuana Registry Program Statistics (April 2018), 88,946 patients in the US have an active medical cannabis registration (10.79 patients out of 1,000 state residents) and more than 30,000 people use cannabis medicinally in the UK each day. Medical cannabis (the plant itself or drugs that are cannabis-derived) is legal in many countries – Argentina, Australia, Canada, Chile, Colombia, Croatia, Cyprus, Denmark, Finland, Germany, Greece, Italy, Macedonia, Malta and The Netherlands, to name a few.
The Cannabis pharmaceutical and medical industry
Endocannabinoids and their known receptors are found throughout the human body, in the nervous system, some internal organs, connective tissues, glands, and immune cells. The endocannabinoids system has a homeostatic role, having been characterized as “eat, sleep, relax, forget, and protect.”. It is known that this system has an avtive role in the pathology of many disorders while also serving a protective function in certain medical conditions.
There is no wonder, therefore, that dozens of pharmaceutical and biotech companies are activly trying to pursue the goal of developing cannabis based medicines.
The most updated estimates are that the Cannabis pharmaceutical and medical industry will spend more than $1 billion in 2019 while trying to transform Cannabis into medicine. Servicing this industry is the goal of Biobis Pharma.
Medical cannabis can be administered through a variety of methods, including capsules, lozenges, tinctures, dermal patches, oral or dermal sprays, cannabis edibles, and vaporizing or smoking dried buds.